Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00946998 · ClinicalTrials.gov registry record · Phase 3
Chronic Kidney Disease Antidepressant Sertraline Trial
A Phase 3 study, sponsored by VA Office of Research and Development.
- Completed
- Registry status
- Phase 3
- Development phase
- 201
- Enrollment target
NCT00946998: Completed Phase 3 study, sponsored by VA Office of Research and Development.
NCT00946998 is a Phase 3 study that has completed, run by VA Office of Research and Development. The registered enrollment target is 201 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00946998, a Phase 3 study, has completed, sponsored by VA Office of Research and Development.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 201 participants
- Enrollment target
Study Summary
This is a randomized double-blinded placebo-controlled trial to see if treatment with sertraline as compared with placebo tablets will improve depression symptoms in patients with chronic kidney disease who have not yet started dialysis or received a kidney transplant. The investigators will also investigate whether sertraline treatment will improve quality of life and whether it is safe to use in patients with kidney disease. The study subject will be randomly assigned to take either sertraline or a placebo tablet for 12 weeks.
Interventions
- DRUG placebo
- DRUG Sertraline
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 201 participants |
| Start Date | 2010-02-08 |
| Est. Completion | 2017-11 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00946998
The ClinicalTrials.gov registry entry for NCT00946998 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 201 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is VA Office of Research and Development, which has 1,668 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which placebo is the first listed.
NCT00946998 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00946998 about?
NCT00946998 is a clinical study titled "Chronic Kidney Disease Antidepressant Sertraline Trial". This is a randomized double-blinded placebo-controlled trial to see if treatment with sertraline as compared with placebo tablets will improve depression symptoms in patients with chronic kidney disease who have not yet started dialysis or received a kidney transplant. The investigators will also in...
What is the current status of trial NCT00946998?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 201 participants. The study started on 2010-02-08. Estimated completion is 2017-11.
What interventions are being tested in trial NCT00946998?
The interventions under investigation include: placebo (DRUG), Sertraline (DRUG).
Who is sponsoring clinical trial NCT00946998?
This trial is sponsored by VA Office of Research and Development, which has 1,668 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.